tiprankstipranks
Rafael Holdings Inc (RFL)
NYSE:RFL
US Market
Want to see RFL full AI Analyst Report?

Rafael Holdings (RFL) AI Stock Analysis

204 Followers

Top Page

RFL

Rafael Holdings

(NYSE:RFL)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 5.2)
Rating:51Neutral
Price Target:
$2.00
▼(-6.10% Downside)
Action:Reiterated
Date:07/08/26
The score is held down primarily by very weak financial performance (persistent large losses and cash burn despite low leverage). Technicals are moderately supportive with improving momentum and price above key longer-term moving averages, and corporate events are a notable positive due to Phase 3 completion and expanded IP—partly offset by limited valuation support given ongoing losses and no dividend yield.
Positive Factors
Pivotal Phase 3 completion
Completing a large pivotal Phase 3 with supportive pediatric data and no serious drug-related adverse events materially de-risks clinical development. The pre-NDA meeting and expanded access acknowledgement indicate a clear regulatory path to commercialization, supporting durable future revenue prospects and partner interest.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow implies the business relies on balance sheet resources or external financing to sustain operations. Over months this constrains strategic options, raises dilution or funding risk, and can limit the company's ability to scale commercialization or advance multiple programs concurrently.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Phase 3 completion
Completing a large pivotal Phase 3 with supportive pediatric data and no serious drug-related adverse events materially de-risks clinical development. The pre-NDA meeting and expanded access acknowledgement indicate a clear regulatory path to commercialization, supporting durable future revenue prospects and partner interest.
Read all positive factors

Rafael Holdings (RFL) vs. SPDR S&P 500 ETF (SPY)

Rafael Holdings Business Overview & Revenue Model

Company Description
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are str...
How the Company Makes Money
Rafael Holdings generates (or has generated) earnings primarily through (1) investment returns and monetization related to its interests in life-science/pharmaceutical assets and companies (e.g., proceeds from equity interests, licensing, mileston...

Rafael Holdings Financial Statement Overview

Summary
Overall financial quality is weak: TTM revenue is small and declining while losses and margins are deeply negative, and operating/free cash flow remain meaningfully negative (continued cash burn). The main offset is a relatively strong balance sheet with very low leverage, but equity/assets have trended down and returns are sharply negative, indicating ongoing value erosion.
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
BreakdownTTMJul 2025Oct 2024Jul 2023Oct 2022Jul 2021
Income Statement
Total Revenue980.00K917.00K637.00K279.00K410.00K802.00K
Gross Profit777.00K495.00K483.00K279.00K410.00K802.00K
EBITDA-31.00M-32.25M-66.79M-8.67M-139.89M-23.34M
Net Income-32.55M-30.52M-34.41M-1.88M-124.66M-24.54M
Balance Sheet
Total Assets91.99M114.11M96.83M98.83M118.32M154.06M
Cash, Cash Equivalents and Short-Term Investments30.50M52.77M65.94M79.51M63.23M7.85M
Total Debt610.00K692.00K2.39M0.0015.00M14.53M
Total Liabilities11.19M15.74M10.57M2.20M21.11M17.35M
Stockholders Equity75.39M94.39M82.19M100.29M100.52M122.29M
Cash Flow
Free Cash Flow-31.98M-18.93M-7.98M40.79M-26.08M-15.81M
Operating Cash Flow-31.98M-18.92M-7.80M-10.89M-26.08M-15.60M
Investing Cash Flow-516.00K44.03M-10.82M21.21M-63.80M-7.26M
Financing Cash Flow24.79M24.83M-179.00K-15.22M103.86M29.39M

Rafael Holdings Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.13
Price Trends
50DMA
2.20
Negative
100DMA
1.74
Positive
200DMA
1.51
Positive
Market Momentum
MACD
-0.10
Positive
RSI
45.41
Neutral
STOCH
20.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RFL, the sentiment is Neutral. The current price of 2.13 is below the 20-day moving average (MA) of 2.15, below the 50-day MA of 2.20, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 20.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RFL.

Rafael Holdings Risk Analysis

Rafael Holdings disclosed 78 risk factors in its most recent earnings report. Rafael Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Rafael Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
64
Neutral
$350.73M-54.61-11.91%46.70%61.90%
61
Neutral
$665.51M-38.14-7.05%4.94%5.32%3.15%
57
Neutral
$306.93M417.510.08%-5.43%-93.40%
54
Neutral
$8.51B654.60-40.26%40.10%
51
Neutral
$100.90M-2.84-38.97%33.88%26.75%
48
Neutral
$153.63M84.503.26%-5.23%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RFL
Rafael Holdings
2.02
0.34
20.24%
RMAX
Re/Max Holdings
10.77
2.77
34.62%
AGNT
eXp World Holdings
4.13
-5.84
-58.56%
REAX
Real Brokerage
1.99
-2.10
-51.34%
COMP
Compass
12.58
4.37
53.23%
DOUG
Douglas Elliman Inc.
1.79
-0.34
-15.96%

Rafael Holdings Corporate Events

Business Operations and StrategyProduct-Related Announcements
Rafael Holdings Completes Pivotal Phase 3 TransportNPC Study
Positive
Jun 10, 2026
On June 10, 2026, Rafael Holdings announced that the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C, involving 94 patients across 27 sites in 13 countries,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2026